Business
Lilly raises outlook for third time this year as Zepbound sales soar.
Headline as filed by MarketWatch.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| MarketWatch | Lilly raises outlook for third time this year as Zepbound sales soar. |
The drug continues do dominate the market for prescription weight-loss drugs in the U.S. |
0m | marketwatch.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.